Characteristics of patients and transplants
| Variable . | No. of patients, n = 294 (%) . |
|---|---|
| Age group at transplant, y | |
| ≤ 30 | 7 (2) |
| > 30-40 | 30 (10) |
| > 40-50 | 109 (37) |
| > 50-60 | 123 (42) |
| > 60 | 25 (9) |
| Sex | |
| Male | 158 (54) |
| Female | 136 (46) |
| Disease status | |
| Complete remission | 99 (34) |
| Not in complete remission | 178 (61) |
| Unknown | 17 (6) |
| Conditioning regimen | |
| Myeloablative | 102 (34) |
| Reduced intensity | 128 (44) |
| Unclassifiable | 64 (22) |
| GVHD prophylaxis* | |
| Cyclosporine-based | 195 (66) |
| Tacrolimus-based | 94 (32) |
| Other | 5 (2) |
| Source of stem cells | |
| Bone marrow | 132 (45) |
| Peripheral blood | 111 (38) |
| Bone marrow + peripheral blood | 2 (1) |
| Cord blood | 49 (17) |
| Type of donor† | |
| HLA-matched related | 132 (45) |
| HLA-mismatched related | 31 (11) |
| Unrelated, bone marrow | 82 (28) |
| Unrelated, cord blood | 49 (17) |
| Time from diagnosis to transplant | |
| ≤ 6 mo | 141 (48) |
| > 6 mo | 141 (48) |
| Uncertain/missing | 12 (4) |
| Year of transplant | |
| 1995-1999 | 22 (7) |
| 2000-2002 | 91 (31) |
| 2003-2005 | 181 (62) |
| Follow-up of survivors | |
| Median time, mo (range) | 42.8 (1.5-102.3) |
| Variable . | No. of patients, n = 294 (%) . |
|---|---|
| Age group at transplant, y | |
| ≤ 30 | 7 (2) |
| > 30-40 | 30 (10) |
| > 40-50 | 109 (37) |
| > 50-60 | 123 (42) |
| > 60 | 25 (9) |
| Sex | |
| Male | 158 (54) |
| Female | 136 (46) |
| Disease status | |
| Complete remission | 99 (34) |
| Not in complete remission | 178 (61) |
| Unknown | 17 (6) |
| Conditioning regimen | |
| Myeloablative | 102 (34) |
| Reduced intensity | 128 (44) |
| Unclassifiable | 64 (22) |
| GVHD prophylaxis* | |
| Cyclosporine-based | 195 (66) |
| Tacrolimus-based | 94 (32) |
| Other | 5 (2) |
| Source of stem cells | |
| Bone marrow | 132 (45) |
| Peripheral blood | 111 (38) |
| Bone marrow + peripheral blood | 2 (1) |
| Cord blood | 49 (17) |
| Type of donor† | |
| HLA-matched related | 132 (45) |
| HLA-mismatched related | 31 (11) |
| Unrelated, bone marrow | 82 (28) |
| Unrelated, cord blood | 49 (17) |
| Time from diagnosis to transplant | |
| ≤ 6 mo | 141 (48) |
| > 6 mo | 141 (48) |
| Uncertain/missing | 12 (4) |
| Year of transplant | |
| 1995-1999 | 22 (7) |
| 2000-2002 | 91 (31) |
| 2003-2005 | 181 (62) |
| Follow-up of survivors | |
| Median time, mo (range) | 42.8 (1.5-102.3) |
Data are numbers (%) unless specified otherwise.
Cyclosporine-based indicates cyclosporine with or without other agents; tacrolimus-based indicates tacrolimus with or without other agents.
HLA compatibility was defined according to the results of serologic or low-resolution molecular typing for HLA-A, B, and DR antigens.